CHYMICUS UK LIMITED 14465001 true 2022-11-07 2023-11-30 2023-11-30 The principal activity of the company is dormant company Digita Accounts Production Advanced 6.30.9574.0 true C Prom 14465001 2022-11-07 2023-11-30 14465001 2023-11-30 14465001 bus:Director1 2023-11-30 14465001 core:ShareCapital 2023-11-30 14465001 core:CurrentFinancialInstruments 2023-11-30 14465001 bus:FRS102 2022-11-07 2023-11-30 14465001 bus:AuditExempt-NoAccountantsReport 2022-11-07 2023-11-30 14465001 bus:FullAccounts 2022-11-07 2023-11-30 14465001 bus:RegisteredOffice 2022-11-07 2023-11-30 14465001 bus:Director1 2022-11-07 2023-11-30 14465001 bus:EntityHasNeverTraded 2022-11-07 2023-11-30 14465001 bus:PrivateLimitedCompanyLtd 2022-11-07 2023-11-30 14465001 countries:EnglandWales 2022-11-07 2023-11-30 iso4217:GBP xbrli:pure

Registration number: 14465001

CHYMICUS UK LIMITED

Annual Report and Unaudited Financial Statements

for the Period from 7 November 2022 to 30 November 2023

 

CHYMICUS UK LIMITED

Director's Report for the Period from 7 November 2022 to 30 November 2023

The director presents his report and the financial statements for the period from 7 November 2022 to 30 November 2023.

Incorporation

The company was incorporated on 7 November 2022.

Director of the company

The director who held office during the period was as follows:

C Prom (appointed 7 November 2022)

Small companies provision statement

This report has been prepared in accordance with the small companies regime under the Companies Act 2006.

Approved and authorised by the director on 5 August 2024
 

.........................................
C Prom
Director

 

CHYMICUS UK LIMITED

Profit and Loss Account for the Period from 7 November 2022 to 30 November 2023

The company has not traded during the period. During this period, the company received no income and incurred no expenditure and therefore made neither profit nor loss.

 

CHYMICUS UK LIMITED

(Registration number: 14465001)
Balance Sheet as at 30 November 2023

Note

2023
£

Current assets

 

Debtors

4

1

Net assets

 

1

Capital and reserves

 

Called up share capital

1

Shareholders' funds

 

1

For the financial period ending 30 November 2023 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the director on 5 August 2024
 


C Prom
Director

 

CHYMICUS UK LIMITED

Notes to the Unaudited Financial Statements for the Period from 7 November 2022 to 30 November 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Windsor House
Bayshill Road
Cheltenham
Gloucestershire
GL50 3AT

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Judgements

No significant judgements have been made by management in preparing these financial statements.

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

CHYMICUS UK LIMITED

Notes to the Unaudited Financial Statements for the Period from 7 November 2022 to 30 November 2023

Financial instruments

Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

 Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

 Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

3

Staff numbers

The average number of persons employed by the company (including the director) during the period, was 0.

4

Debtors

2023
£

Amounts owed by related parties

1